Biocartis believes in the power of collaboration and has active partnership programs with both pharmaceutical companies & diagnostic or biomarker companies
Partnering with Biocartis
Rooted in continuous scientific breakthroughs, the future of medicine will be increasingly personalized, predictive, preventive and precise as more and more molecular information can be obtained from an individual patient.
Therefore, Biocartis is convinced that molecular diagnostics solutions need to be more easily available to patients and physicians.
Biocartis’ mission is to become a leading player in the molecular diagnostics space by providing innovative personalized healthcare solutions allowing instant, global access to accurate, ‘first time right’ molecular information from any biological sample. Biocartis enables fast and effective diagnosis, disease staging, treatment selection and treatment progress monitoring.
The company’s flagship product, Idylla™, is a versatile best-in-class sample-to-result molecular diagnostics platform that makes molecular testing convenient, fast and suitable for any lab.
Meet Idylla
The Idylla Platform is the first random-access sample-to-result platform to offer a broad menu of molecular diagnostics (MDx) tests in the oncology field complemented with offerings in the infectious disease area.
Most oncology MDx testing is performed on high-throughput batch-based MDx systems in either commercial service laboratories or specialized hospital associated labs. The workflow of such systems consists in general of multiple instruments and requires multiple manual interventions in order to perform all the steps from sample preparation to result analysis. This set-up drives the need for a multi-room lab infrastructure (to avoid contamination), a batch-based testing approach (testing multiple patient samples requiring the same analysis in parallel), experienced and specifically trained laboratory technicians and the consumption of a large variety of ancillary laboratory consumables. The high-throughput batch-based MDx systems can be based on a qPCR biomarker detection technology but also other detection technologies such as sequencing, mass spectrometry or digital droplet PCR.
In contrast to the foregoing workflow, an Idylla™ based workflow comes with simple instrument requirements, a fully automated workflow, random-access testing (no need for batching), a single-room laboratory infrastructure, minimal hands-on time and lab consumable needs as well as lower technical requirements for laboratory personnel. All of these advantages support increased and much faster access to actionable molecular test results irrespective of hospital size.
